INTRODUCTION
Driver mutations in the EGFR gene are found in a subset of lung adenocarcinomas and define cancers in which tumor cell survival is exquisitely dependent on epidermal growth factor receptor (EGFR) pathway signaling. 1 The addiction to EGFR signaling leaves the cancers uniquely susceptible to selective oral EGFR tyrosine kinase inhibitors (TKIs), 1 and patients with advanced EGFR-mutant non-smallcell lung cancer (NSCLC) may experience dramatic tumor shrinkage and durable responses with the reversible EGFR TKIs gefitinib and erlotinib. Randomized phase III clinical trials have demonstrated that personalizing first-line treatment by EGFR mutation status with these EGFR TKIs leads to improvement in progression-free survival (PFS) compared with chemotherapy. [2] [3] [4] [5] [6] The trials have all used platinum doublet chemotherapy combinations with a taxane or gemcitabine as the second
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drug in the regimen. Recently, pemetrexed has become a preferential drug for patients with lung adenocarcinoma; randomized trials have shown it yields favorable responses and survival with better tolerability compared with taxanes and gemcitabine in those with nonsquamous NSCLC. [7] [8] [9] First-line, genotype-directed EGFR inhibition has yet to be compared against pemetrexed-containing chemotherapy.
Afatinib is an orally available, irreversibly binding ErbB family blocker with the ability to block signaling from EGFR (ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), ErbB4, and all relevant ErbB family dimers. 10,10a In vitro, the median inhibitory concentration is lower than those of currently available EGFR TKIs. 10 In a large phase II study of EGFR-mutant NSCLC, the response rate to afatinib was 61% (independent review), with median PFS of 12 months for treatmentnaive patients and 8 months for EGFR TKI-naive patients after first-line chemotherapy.
11 To determine if EGFR genotype-directed therapy with afatinib is superior to pemetrexed-based chemotherapy, we embarked on the LUX-Lung 3 randomized phase III trial.
PATIENTS AND METHODS

Study Design and Patients
LUX-Lung 3 was a global, randomized, open-label phase III study comparing first-line afatinib with cisplatin plus pemetrexed chemotherapy in patients with advanced lung adenocarcinoma and proven EGFR mutations. The primary end point was PFS, defined as time from random assignment to progression (as determined by independent blinded review) or death.
To qualify for enrollment, a patient's tumor had to harbor an activating mutation in EGFR when tested at one of three central laboratories employing a standardized allele-specific quantitative real-time polymerase chain reaction kit (Therascreen EGFR 29; Qiagen, Manchester, United Kingdom). In addition, eligible patients had treatment-naive advanced lung adenocarcinoma; good performance status, defined as 0 or 1 on the Eastern Cooperative Oncology Group scale
12
; adequate end-organ function; and measurable disease using RECIST version 1.1.
13 A list of the EGFR mutations detectable by Therascreen and the full eligibility criteria are provided in the protocol.
Secondary end points included objective response (complete response [CR] and partial response [PR] ) and disease control (CR/PR ϩ stable disease [SD] ) and their duration, overall survival (OS), patientreported outcomes (PROs), treatment safety, adverse event (AE) profiles, and pharmacokinetics of afatinib.
Treatment
Patients were randomly assigned in a two-to-one fashion to oral afatinib 40 mg once per day or intravenous cisplatin 75 mg/m 2 and pemetrexed 500 mg/m 2 once every 21 days up to a maximum of six cycles. Randomization was stratified by type of EGFR mutation (L858R, exon 19 deletion, or other) and race (Asian or non-Asian). Patients randomly assigned to afatinib were permitted to dose escalate to 50 mg daily after the first 21-day cycle if they did not experience rash, diarrhea, mucositis, or any other drug-related AE Ͼ grade 1 in severity. Patients randomly assigned to chemotherapy received folic acid, vitamin B12, and dexamethasone, as per package recommendations for pemetrexed. No maintenance chemotherapy was permitted. Treatment continued until investigator-assessed progression. Recommendations for management of AEs and dose reductions were provided to all investigators, including reduction of afatinib by 10-mg decrements down to 20 mg per day for treatment-related grade 3 or selected prolonged grade 2 AEs according to the NCI-CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events).
Assessments
Tumor assessments were performed by computed tomography or magnetic resonance imaging every 6 weeks for the first 48 weeks and then every 12 weeks thereafter until disease progression or start of new anticancer therapy.
Scans were reviewed by an independent central imaging group incorporating both radiologist and oncologist reviewers blinded to treatment assignments. PROs were assessed every 21 days until disease progression or start of new anticancer therapy using the EORTC QLQ-C30 (European Organisation for  Research and Treatment of Cancer Core Quality of Life Questionnaire)  14 and  EORTC QLQ-LC13 (lung cancer-specific module) 15 questionnaires. PROs were assessed per standard published EORTC algorithms, including time to deterioration of symptoms calculated as the time from random assignment to the first 10-point worsening from the baseline score (considered clinically meaningful). 16, 17 Analyses reported here focused on three common lung cancer-related symptoms: cough (Q1 of LC13), dyspnea (Q3 and Q5 of LC13), and pain (Q9 and Q19 of C30). Detailed analyses of these outcomes have been reported elsewhere.
17a
AEs were categorized and graded using NCI-CTCAE version 3.0. 18 An independent data safety monitoring board conducted ongoing assessments of efficacy and safety data. Afatinib plasma concentrations were analyzed by validated high-performance liquid chromatography tandem mass spectrometry.
Statistical and Regulatory Considerations
The trial sponsor collected and analyzed the data; the lead investigators had full access to the data. The sample size was specified assuming a hazard ratio (HR) of 0.64, equating to an increase in median PFS from an expected 7 months for chemotherapy to 11 months for afatinib. To provide 90% power at a two-sided 5% significance level, 217 progression or death events were required. The samples size was calculated to be 330 patients and the estimated time of primary analysis to be approximately 2 years after study initiation. No interim analyses to compare treatment arms were planned. All efficacy analyses were performed in an intent-to-treat manner and included all randomly assigned patients. The comparison of PFS between arms was calculated by a stratified log-rank test, using the same stratification factors used in randomization. Cox proportional hazard models were used to compare PFS between arms, and Kaplan-Meier estimates were calculated. PFS analysis in patients with common EGFR mutations (L858R and exon 19 deletions) was prespecified. Median follow-up time was calculated with the reverse Kaplan-Meier method. Response rate was defined for each arm as the proportion of patients with best overall RECIST response of CR or PR, divided by the total number of patients randomly assigned to that arm; logistic regression models were used to compare arms.
Safety analyses included all patients receiving at least one dose of trial medication. Descriptive statistics were used for all other secondary and exploratory analyses. The primary analysis for OS is scheduled to occur when approximately 209 deaths are observed.
RESULTS
Patients
This study was performed at 133 centers in 25 countries in Asia, Europe, North America, South America, and Australia. Between August 2009 and February 2011, 1,269 patients were screened to identify and randomly assign 345 eligible patients with EGFR mutations (Fig  1) . Median laboratory turnaround time for EGFR mutation analysis was 5 days (range, 1 to 15 days). Five randomly assigned patients withdrew before receiving any study medication.
Treatment arms were balanced in terms of patient demographics and clinical characteristics ( Table 1) . As expected for a population selected by virtue of EGFR mutations, 72% of patients were East Asian, 68% were never-smokers, and 65% were women. EGFR mutations were predominantly exon 19 deletions (49%) and L858R point mutations (40%).
Treatment Delivery and Efficacy
Afatinib was administered for a median of 11.0 months (16 cycles). Meanoverallcompliancewithafatinibassessedperpatientwas98%.Dose reduction to less than 40 mg per day was required for 120 patients (52%), with 43 (19%) having more than one dose reduction. Five patients erroneously began afatinib at 50 mg per day, and 16 (7%) exercised the option to increase from 40 to 50 mg per day after the first cycle. Median number of chemotherapy cycles was six; 83 patients (75%) received Ն four cycles, and 61 (55%) received all six cycles. Eighteen patients (16%) had a chemotherapy dose reduction for AEs, and treatment administration was delayed by Ն 6 days in 41 patients (40%).
At the time of data cutoff for the primary analysis, median follow-up time was 16.4 months, and 221 progression or death events, as assessed by independent review, had occurred. The primary end point-PFS assessed by independent review-was significantly prolonged for patients receiving afatinib compared with cisplatin plus pemetrexed; median PFS was 11.1 and 6.9 months, respectively (HR, 0.58; 95% CI, 0.43 to 0.78; P ϭ .001; Fig 2A) . Investigator-reviewed PFS yielded similar results (Fig 3A) . At the time of data cutoff, investigators had observed 238 PFS events, with a median PFS of 11.1 months for afatinib and 6.7 months for chemotherapy (HR, 0.49; 95% CI, 0.37 to 0.65; P ϭ .001).
Several previous phase III studies included only common sensitizing EGFR mutations (L858R and exon 19 deletions). 3, 5, 6 In our study, the preplanned analysis of those with common EGFR mutations (n ϭ 308) showed the magnitude of PFS benefit was even larger, with a median PFS (by independent review) of 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P ϭ .001; Fig 2B) . By investigator assessment, HR was 0.41 (95% CI, 0.31 to 0.55; P ϭ .001). Subgroup analyses showed the PFS benefit for afatinib persisted among most clinically relevant subgroups examined (age, sex, race, Eastern Cooperative Oncology Group status), although many subgroups were underpowered for meaningful conclusions (Fig 2C) . Subgroup analyses using investigator-determined PFS yielded similar results (Fig 3B) . Exploratory subgroup analyses for common mutations are shown in Appendix Figure A1 (online only). The numbers of uncommon mutations were too small (26 in afatinib arm; 11 in chemotherapy arm) for further analysis, although outcomes for those receiving afatinib will be analyzed together with those for patients with uncommon mutations from other afatinib studies.
Significantly higher response rates were observed with afatinib compared with chemotherapy according to both independent (56% and 23%, respectively) and investigator (69% and 44%, respectively) assessments (both P ϭ .001). Both treatment arms had a high proportion of patients achieve disease control (90% in afatinib arm; 81% in chemotherapy arm, by independent review). Median duration of response was independently assessed as 11.1 and 5.5 months for afatinib and chemotherapy, respectively, whereas median duration of disease control was 13.6 and 8.1 months, respectively. At the time of data cutoff, only 98 patients (28%) had died; hence, the OS data are considered preliminary. OS did not differ between afatinib and chemotherapy in the overall study population (HR, 1.12; 95% CI, 0.73 to 1.73; P ϭ .60; 25th percentile, 16.6 v 14.8 months). Median OS has not yet been reached for any group. A high degree of postprogression crossover to EGFR TKIs among patients receiving chemotherapy (65%) and to chemotherapy among those receiving afatinib (62%) was observed.
For PROs, prespecified analyses of time to deterioration of symptoms and clinically meaningful worsening of cough (HR, 0.60; 95% CI, 0.41 to 0.87; P ϭ .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P ϭ .01) showed significant delay with afatinib compared with chemotherapy. Time to deterioration of pain was also longer with afatinib, but it was not statistically significant (HR, 0.83; 95% CI, 0.62 to 1.10; P ϭ .19).
Treatment-Related AEs
Both treatments were well tolerated, and AEs were manageable with dose reductions and delays. Treatment-related AEs grade Ն 3 occurred in 112 patients (49%) receiving afatinib and 53 patients (48%) receiving chemotherapy. Diarrhea, rash, and dryness or irritation of the skin, mucosa, and nails were the most common treatment-related AEs with afatinib, whereas decreased appetite, fatigue, nausea/vomiting, and myelosuppression were most common with chemotherapy (Table 2) . Therapy was discontinued because of treatment-related AEs in 8% of those receiving afatinib and 12% of those receiving chemotherapy. Of the most common AEs associated with afatinib, only diarrhea (1.3%) and paronychia (0.9%) resulted in treatment discontinuation. There were three cases (1%) of potentially related interstitial lung disease-like events, and four deaths among those receiving afatinib were considered potentially treatment related by the investigator (two respiratory decompensations, one sepsis, and one unknown). There were no treatment-related fatal toxicities in the chemotherapy arm.
Pharmacokinetics
To obtain a comprehensive picture of exposure, predose plasma samples were taken on days 1 and 8 of cycle two and day 1 of cycle three. Afatinib plasma levels showed high interpatient variability. Dose modifications, which were based on individual tolerability, reduced excessive afatinib levels and thus the variability observed in the 40-mg dose group from 85.0% (day 1 of cycle two) to 66.5% (day 1 of cycle three; Appendix Fig A2A, online only) . Ranges and geometric mean values of trough plasma concentrations were comparable for all dose groups at the last pharmacokinetic visit on day 1 of cycle three (Appendix Fig A2B, online only) .
DISCUSSION
To our knowledge, LUX-Lung 3 is the largest prospective, randomized trial reported to date in patients with advanced stage EGFR mutationpositive NSCLC and the first study to compare first-line EGFRtargeted TKI therapy with the best-in-class chemotherapy regimen of cisplatin plus pemetrexed. The study showed a significant PFS benefit for personalized, genotype-directed therapy with the ErbB family blocker afatinib compared with cisplatin plus pemetrexed chemotherapy. In addition, patients treated with afatinib had statistically significant and clinically meaningful improvements in response rate and lung cancer symptoms. Afatinib treatment was associated with manageable AEs, and hence, discontinuation because of drug-related AEs was low. At the time of analysis, no difference in OS between treatment arms was apparent.
The perception of optimal EGFR TKI placement in the treatment algorithms for NSCLC has evolved over the last decade. Gefitinib and erlotinib were initially considered salvage therapies, with low response rates but marginal improvement in survival compared with placebo in unselected patients. 19, 20 Once the qualitative difference in response to EGFR TKIs among EGFR-mutant patients was appreciated, randomized studies were performed in Asian patients comparing gefitinib or erlotinib with taxane-and gemcitabine-based chemotherapy. [2] [3] [4] [5] These showed remarkable PFS improvement, but questions as to whether benefit was restricted to Asian patients arose. The recent EURTAC (European Tarceva versus Chemotherapy) study using erlotinib in European patients 6 and our study using afatinib in patients from around the world clearly support initial EGFR TKI treatment in patients with EGFR mutation-positive NSCLC, regardless of race. EGFR testing should be tightly woven into lung cancer diagnostic workup algorithms worldwide.
Key strengths of this study were central EGFR mutation testing and central review of radiographs. Molecular testing methods are essential components of biomarker-directed therapy. The sensitivity and specificity of EGFR mutation screening methods vary, 21 and calculated PFS statistics for EGFR mutation-positive patients may vary within the same overall cohort of gefitinib-treated patients when different EGFR mutation detection methods are used. 22 Therefore, standardization of the testing assay and methodology is crucial to define the population to be treated and assure reproducibility of results. Central radiology interpretation is important to reduce bias in the interpretation of PFS. In our study, disease progression was recorded by investigators more often than by independent reviewers, particularlyamongpatientsrandomlyassignedtochemotherapy(chemotherapy arm: 83 progression events by investigators v 69 by independent review; afatinib arm: 155 by investigators v 152 by central review). It is possible that investigators were more likely to stop chemotherapy than afatinib in patients known to harbor EGFR mutations. In the primary analysis, any events reported by investigators that were nonevents by independent review were censored at the time of discrepancy; therefore, the true treatment effect could have been underestimated, as was shown in several preplanned sensitivity and subgroup analyses using investigator-generated progression events. Despite the high response rate and prolonged PFS of patients with EGFR mutations treated with gefitinib or erlotinib, there are still major clinical obstacles. Approximately half of those with EGFR mutations will develop the T790M resistance mutation when their tumors are rebiopsied after treatment with erlotinib or gefitinib. [23] [24] [25] T790M mutations may already be present in EGFR TKI treatmentnaive patients, 26, 27 and the presence of a detectable de novo T790M mutation predicts for shorter PFS with EGFR TKIs. 26, 28, 29 Afatinib had in vitro activity against the T790M variant 10 and improved PFS compared with placebo in a randomized phase III trial in an NSCLC population clinically enriched for the presence of such mutations. 30 Therefore, afatinib may inhibit the selective expansion of T790M clones and prolong PFS. Afatinib-treated patients with exon 19 deletion and L858R mutations had a prolonged PFS of 13.6 months.
An important accompaniment to PFS gains with a genotypedirected therapeutic strategy is improvement in PROs. 31 We demonstrated clinically meaningful delays in worsening of lung cancerrelated symptoms in afatinib-treated patients compared with those treated with chemotherapy. The AE profile of afatinib was manageable Time (months) Progression-Free Survival (probability) and consisted primarily of rash, diarrhea, stomatitis, and paronychia, as expected from EGFR inhibition. [2] [3] [4] [5] [6] Despite higher frequencies of such AEs in our trial, these AEs rarely led to drug discontinuation, indicating that proactive supportive treatment and dose modification were an adequate strategy to properly manage the expected class effects associated with EGFR inhibition. In addition, the results of the pharmacokinetic analysis indicate that afatinib dose modification based on individual tolerability optimized the exposure to afatinib and maintained efficacious plasma levels.
Cisplatin plus pemetrexed is widely considered the optimal chemotherapy doublet for patients with nonsquamous NSCLC. The efficacy of this regimen is supported by the PFS observed in our control arm, which exceeded the results observed in other studies comparing EGFR TKIs with first-line chemotherapy. [2] [3] [4] [5] [6] One of the limitations of our study is that the chemotherapy arm was devoid of maintenance pemetrexed and/or bevacizumab. However, at the time of study design, cisplatin plus pemetrexed without maintenance was considered an efficacious treatment choice for patients with adenocarcinoma.
31a The prevailing treatment standard changed after LUX-Lung 3 accrual was completed, when the results of a trial of maintenance pemetrexed after cisplatin plus pemetrexed showed significant improvement compared with placebo, with a median PFS of 6.9 months.
32 Another limitation is that bevacizumab treatment was not included in the comparator arm of this study. There were two reasons for this: first, although addition of bevacizumab to paclitaxel plus carboplatin is a standard regimen in the United States, 33 bevacizumab use is not standard around the world; similarly, the addition of bevacizumab to cisplatin and pemetrexed is not a current standard regimen.
In conclusion, patients with lung adenocarcinoma with EGFR mutations have significant PFS, tumor response, and lung cancerrelated symptom benefits when treated with first-line afatinib compared with cisplatin plus pemetrexed. Afatinib could be considered a standard option for such patients. 27. Rosell R, Molina MA, Costa C, et al: Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-smallcell lung cancer patients with EGFR mutations. Clin Cancer Res 17:1160 Res 17: -1168 Res 17: , 2011 28. Gazdar AF: Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors. 
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
